Vincenzo Emanuele Chiurì

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev et al. · The Lancet Oncology · 2018 · 405 citations · Full text

Urology, Oncology, Genitourinary Cancer +5

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone

Cristian Lolli, Orazio Caffo, Emanuela Scarpi et al. · Frontiers in Pharmacology · 2016 · 198 citations · Full text

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

Giuseppe Procopio, Giulia Apollonio, Francesco Cognetti et al. · European Urology Oncology · 2019 · 52 citations

Urology, Surgical Oncology, Genitourinary Cancer +5

Real-world Cabazitaxel Safety: The Italian Early-Access Program in Metastatic Castration-Resistant Prostate Cancer

Sergio Bracarda, Angela Gernone, Donatello Gasparro et al. · Future Oncology · 2013 · 49 citations · Full text

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Fred Saad, Antoine Thiery-Vuillemin, Paweł Wiechno et al. · The Lancet Oncology · 2022 · 30 citations

Urology, Patient-reported Outcomes, Medicine +8